Copyright independent
Teva Pharmaceuticals has voluntarily recalled over 580,000 bottles of its Prazosin Hydrochloride blood pressure capsules. The recall, issued on 7 October, was due to FDA tests revealing elevated levels of the potentially cancer-causing chemical N-nitroso Prazosin impurity C. Prazosin, also known as Minipress, is an alpha-blocker used to treat high blood pressure, with alternative treatments readily available. The FDA classified this as a Class II recall, indicating that while the drug may cause temporary or reversible health effects, serious harm is considered unlikely. Teva USA assessed the overall patient risk as medium and has not yet received any relevant complaints regarding the recalled medication.
